Ascletis Pharma Inc. Logo

Ascletis Pharma Inc.

ASCLF

(0.0)
Stock Price

0,24 USD

-0.82% ROA

-11.43% ROE

-9x PER

Market Cap.

173.247.338,00 USD

0.36% DER

0% Yield

-2561.68% NPM

Ascletis Pharma Inc. Stock Analysis

Ascletis Pharma Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Ascletis Pharma Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Ascletis Pharma Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Ascletis Pharma Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Sell
4 Stoch RSI Buy

Ascletis Pharma Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Ascletis Pharma Inc. Revenue
Year Revenue Growth
2016 32.976.000
2017 53.202.000 38.02%
2018 256.256.000 79.24%
2018 166.325.000 -54.07%
2019 173.443.000 4.1%
2020 35.001.000 -395.54%
2021 76.876.000 54.47%
2022 54.090.000 -42.13%
2023 5.582.408 -868.94%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Ascletis Pharma Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2016 62.689.000
2017 114.325.000 45.17%
2018 147.664.000 22.58%
2018 143.452.000 -2.94%
2019 125.962.000 -13.89%
2020 109.099.000 -15.46%
2021 213.320.000 48.86%
2022 267.102.000 20.14%
2023 65.865.808 -305.52%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Ascletis Pharma Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 15.044.000
2017 37.477.000 59.86%
2018 122.620.000 69.44%
2018 85.789.000 -42.93%
2019 24.543.000 -249.55%
2020 20.437.000 -20.09%
2021 16.491.000 -23.93%
2022 15.429.000 -6.88%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Ascletis Pharma Inc. EBITDA
Year EBITDA Growth
2016 -38.729.000
2017 -62.161.000 37.7%
2018 43.788.000 241.96%
2018 -48.930.000 189.49%
2019 -14.292.000 -242.36%
2020 -129.266.000 88.94%
2021 -166.351.000 22.29%
2022 -232.626.000 28.49%
2023 -119.851.432 -94.1%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Ascletis Pharma Inc. Gross Profit
Year Gross Profit Growth
2016 32.976.000
2017 53.202.000 38.02%
2018 245.064.000 78.29%
2018 153.946.000 -59.19%
2019 124.283.000 -23.87%
2020 -23.497.000 628.93%
2021 39.173.000 159.98%
2022 -24.692.000 258.65%
2023 -10.015.700 -146.53%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Ascletis Pharma Inc. Net Profit
Year Net Profit Growth
2016 -26.807.000
2017 -53.935.000 50.3%
2018 89.984.000 159.94%
2018 -7.258.000 1339.79%
2019 -95.969.000 92.44%
2020 -209.241.000 54.13%
2021 -199.017.000 -5.14%
2022 -314.843.000 36.79%
2023 -70.903.812 -344.04%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Ascletis Pharma Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 0
2017 0 0%
2018 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Ascletis Pharma Inc. Free Cashflow
Year Free Cashflow Growth
2016 -57.104.000
2017 -234.005.000 75.6%
2018 -156.673.000 -49.36%
2018 -27.533.000 -469.04%
2019 -102.574.000 73.16%
2020 -123.871.000 17.19%
2021 -154.128.000 19.63%
2022 -156.854.000 1.74%
2023 -13.010.707 -1105.58%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Ascletis Pharma Inc. Operating Cashflow
Year Operating Cashflow Growth
2016 -12.498.000
2017 -198.056.000 93.69%
2018 -96.590.000 -105.05%
2018 -8.181.000 -1080.66%
2019 -74.341.000 89%
2020 -84.911.000 12.45%
2021 -146.930.000 42.21%
2022 -142.453.000 -3.14%
2023 -10.659.285 -1236.42%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Ascletis Pharma Inc. Capital Expenditure
Year Capital Expenditure Growth
2016 44.606.000
2017 35.949.000 -24.08%
2018 60.083.000 40.17%
2018 19.352.000 -210.47%
2019 28.233.000 31.46%
2020 38.960.000 27.53%
2021 7.198.000 -441.26%
2022 14.401.000 50.02%
2023 2.351.422 -512.44%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Ascletis Pharma Inc. Equity
Year Equity Growth
2016 409.084.000
2017 869.831.000 52.97%
2018 3.427.412.000 74.62%
2019 3.324.217.000 -3.1%
2020 2.981.650.000 -11.49%
2021 2.729.072.000 -9.26%
2022 2.539.886.000 -7.45%
2023 2.342.066.000 -8.45%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Ascletis Pharma Inc. Assets
Year Assets Growth
2016 536.265.000
2017 991.254.000 45.9%
2018 3.527.603.000 71.9%
2019 3.426.387.000 -2.95%
2020 3.067.072.000 -11.72%
2021 2.829.959.000 -8.38%
2022 2.657.042.000 -6.51%
2023 2.491.009.000 -6.67%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Ascletis Pharma Inc. Liabilities
Year Liabilities Growth
2016 127.181.000
2017 121.423.000 -4.74%
2018 100.191.000 -21.19%
2019 102.170.000 1.94%
2020 85.422.000 -19.61%
2021 100.887.000 15.33%
2022 117.156.000 13.89%
2023 148.943.000 21.34%

Ascletis Pharma Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0.02
Price to Earning Ratio
-9x
Price To Sales Ratio
21.37x
POCF Ratio
-9.1
PFCF Ratio
-7.68
Price to Book Ratio
0.08
EV to Sales
-18.32
EV Over EBITDA
3.69
EV to Operating CashFlow
7.46
EV to FreeCashFlow
6.58
Earnings Yield
-0.11
FreeCashFlow Yield
-0.13
Market Cap
0,17 Bil.
Enterprise Value
-0,15 Bil.
Graham Number
0.99
Graham NetNet
2.07

Income Statement Metrics

Net Income per Share
-0.02
Income Quality
0.99
ROE
-0.01
Return On Assets
-0.11
Return On Capital Employed
-0.18
Net Income per EBT
1
EBT Per Ebit
0.64
Ebit per Revenue
-39.75
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
3.58
Stock Based Compensation to Revenue
0
Gross Profit Margin
-1.25
Operating Profit Margin
-39.75
Pretax Profit Margin
-25.62
Net Profit Margin
-25.62

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.02
Free CashFlow per Share
-0.02
Capex to Operating CashFlow
-0.13
Capex to Revenue
0.33
Capex to Depreciation
1
Return on Invested Capital
-0.02
Return on Tangible Assets
-0.01
Days Sales Outstanding
244.62
Days Payables Outstanding
40.73
Days of Inventory on Hand
381.03
Receivables Turnover
1.49
Payables Turnover
8.96
Inventory Turnover
0.96
Capex per Share
0

Balance Sheet

Cash per Share
2,21
Book Value per Share
2,25
Tangible Book Value per Share
2.22
Shareholders Equity per Share
2.25
Interest Debt per Share
0.01
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
7.99
Current Ratio
16.58
Tangible Asset Value
2,32 Bil.
Net Current Asset Value
2,18 Bil.
Invested Capital
2286930000
Working Capital
2,19 Bil.
Intangibles to Total Assets
0.01
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
6071000
Debt to Market Cap
0.05

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Ascletis Pharma Inc. Dividends
Year Dividends Growth

Ascletis Pharma Inc. Profile

About Ascletis Pharma Inc.

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

CEO
Dr. Jinzi Jason Wu Ph.D.
Employee
219
Address
Building D
Hangzhou,

Ascletis Pharma Inc. Executives & BODs

Ascletis Pharma Inc. Executives & BODs
# Name Age
1 Mr. Ming Fai Chung CPA
Company Secretary
70
2 Dr. Jinzi Jason Wu Ph.D.
Founder, Chairman & Chief Executive Officer
70
3 Ms. Hejingdao Wu
Senior Vice President of Operations & Executive Director
70
4 Ms. Yuemei Yan
Senior Vice President of Clinical Development Operations
70
5 Dr. Kristjan Sigurdur Gudmundsson
Senior Consultant & Head of Discovery
70
6 Dr. George Zhengzhi Hill
Senior Consultant & Chief Medical Advisor
70
7 Mr. John P. Gargiulo M.B.A.
Chief Business Officer
70

Ascletis Pharma Inc. Competitors